TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07896460: A Phase 1, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-92505 Alone and in Combination With Other Antineoplastic Agents in Patients With Advanced Solid Tumors

Sponsor: BeOne Medicines · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 137 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07896460 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07896460 Rescue Dossier →